ABSTRACT NOVEL HETEROCYCLIC COMPOUNDS AS SOS1:KRAS PROTEIN-PROTEIN INTERACTION INHIBITORS The present invention relates to novel compounds of formula (I) which are inhibitors of SOS1:KRAS interaction, their pharmaceutically acceptable esters, salts, solvates, isomers thereof. The present invention specifically...

The present invention relates to novel bicyclic compounds of formula (I) as inhibitors of RAD51 inhibitors, their pharmaceutically acceptable salts, solvates, polymorphs, tautomers, optical and geometric isomers thereof.

The present invention relates to novel compounds of formula (I) which are inhibitors of KRASNODAR interaction, their pharmaceutic ally acceptable esters, salts, solvates, isomers thereof. The present invention specifically relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or a pharmaceu...

The present invention relates to novel heteroaryl compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, polymorphs, tautomers, atropisomers, optical and geometric isomers, prodrugs, or deuterated compounds including other possible isotopes thereof as inhibitors of PKMYT1 The present inventi...

ABSTRACT NOVEL HETEROARYL COMPOUNDS AS USP1 INHIBITORS The present invention relates to novel heteroaryl compounds of formula (I) as USP1 inhibitors, or it’s pharmaceutically acceptable salts, solvates, polymorphs, tautomers, atropisomers, optical and geometric isomers, isotopes, prodrugs or deutera...